News | ACC

March 15, 2018 – A newly-designed wristband and corresponding app that works with a smartwatch can accurately display ...

Home March 15, 2018
Home
News | ACC

March 15, 2018 — For people with heart failure, getting a seasonal influenza (flu) vaccine in a given year was ...

Home March 15, 2018
Home
News | ACC

March 15, 2018 — Women with normal blood pressure during pregnancy and who breastfed their babies for at least six ...

Home March 15, 2018
Home
News | ACC

March 15, 2018 — Women diagnosed with preeclampsia during pregnancy were significantly more likely to develop high blood ...

Home March 15, 2018
Home
News | Antiplatelet and Anticoagulation Therapies

March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of Cardiology ...

Home March 14, 2018
Home
Videos | Sudden Cardiac Arrest

The Zoll LifeVest is a temporary, wearable defibrillator designed as a safety net for patients, especially those being ...

Home March 14, 2018
Home
News | Cardio-oncology

After six months of follow-up, women newly diagnosed with breast cancer who were given the beta blocker carvedilol to prevent heart issues while undergoing chemotherapy showed no difference in declines in heart function compared with those taking a placebo. Patients who took carvedilol, however, were significantly less likely to have an elevated marker in the blood that signals injury to the heart, according to a study being presented at the American College of Cardiology’s (ACC) 67th Annual Scientific Session, March 10-12 in Orlando, Fla.

Home March 14, 2018
Home
News | Cardio-oncology

March 14, 2018 — Breast cancer patients who started taking one of two well-known heart medications at the same time they ...

Home March 14, 2018
Home
News | ACC

March 13, 2018 – Among patients with persistently high cholesterol despite high-intensity statin therapy, the proprotein ...

Home March 13, 2018
Home
News | ACC

March 13, 2018 – Wearing a lightweight vest equipped with a cardioverter defibrillator that detects abnormal heart ...

Home March 13, 2018
Home
News

March 13, 2018 – HeartFlow, Inc. today announced that it has entered into a licensing and technology transfer agreement ...

Home March 13, 2018
Home
News | Intra-Vascular Ultrasound (IVUS)

March 13, 2018 – Infraredx, a company that works in intravascular imaging for mapping coronary artery disease, today ...

Home March 13, 2018
Home
News | Cardiovascular Ultrasound

At the American College of Cardiology’s (ACC) 67th Annual Scientific Session and Expo, March 10-12 in Orlando, Fla., Siemens Healthineers launched its new portable cardiovascular ultrasound solution, the Acuson Bonsai.

Home March 13, 2018
Home
News | Ventricular Assist Devices (VAD)

At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully implantable within the chest experienced no malfunctions requiring replacement or removal of the device for blood clotting. Further, their risk of a stroke was halved compared with patients who received the established version of the pump that requires an abdominal location for the implant, according to research presented at the American College of Cardiology’s 67th Annual Scientific Session, March 10-12 in Orlando, Fla.

Home March 13, 2018
Home
News | Heart Valve Technology

Medtronic plc unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (Nordic Aortic Valve Intervention Trial) at the American College of Cardiology (ACC) 67th Annual Scientific Sessions, March 10-12, 2018, in Orlando Fla. Both studies examined patients with the CoreValve transcatheter aortic valve replacement (TAVR) system at five years post-implant. Results from the studies demonstrated that patients implanted with the CoreValve TAVR system showed strong hemodynamic performance and improved quality of life out to five years.

Home March 12, 2018
Home
Subscribe Now